Viatris faces earnings test as pipeline progress meets pricing pressure

Viatris Inc. is preparing to announce its second-quarter earnings, with analysts anticipating $0.61 EPS on $3.67 billion in revenue. Investors are keenly watching whether the company's recent pipeline successes, such as FDA acceptance for fast-acting meloxicam and positive Phase 3 results for VR-205, can counter industry-wide pricing pressures and drive sustained revenue growth. The market also awaits updates on the search for a permanent CFO following the departure of Theodora Mistras.